Strong laboratory leaders - a key asset for global disease control
Laboratories play an essential role in the detection, diagnosis, prevention and control of diseases. To strengthen this role, ECDC and five partner organisations have developed the Global Laboratory Leadership Programme (GLLP) to support and sustain national laboratory systems under a One Health approach.
Rapid risk assessment: Candida auris in healthcare settings – Europe
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries
Emerging spread of new fungal species poses risk for healthcare settings in the EU/EEA
The rise in Europe of Candida auris infections, a difficult-to-control fungus, is of concern. The fungus spreads easily in healthcare settings, can cause invasive infections, and is also associated with resistance to multiple classes of anti-fungal medication.
Candida auris: Epidemiological situation, laboratory capacity and preparedness in European Union and European economic area countries, 2013 to 2017
Kohlenberg, A., Struelens, M.J., Monnet, D.L., Plachouras, D., Apfalter, P., Lass-Flörl, C., Muchl, R., Presterl, E., Willinger, B., Catry, B., Philipova, I., Budimir, A., Hadjihannas, L., Arendrup, M.C., Märtin, P., Jalava, J., Berger-Carbonne, A., Dromer, F., Kurzai, O., Vrioni, G., Kontopidou, F., Kiss, K., Kurcz, A., Ásmundsdóttir, L.R., Burns, K., Moro, M.L., Dimina, E., Valinteliene, R., Perrin, M., Barbara, C., de Greeff, S., Kacelnik, O., Deptula, A., Rodrigues, M.R., Serban, R., Schréterová, E., Stefkovicova, M., Serdt, M., Alastruey-Izquierdo, A., Pemán, J., Byfors, S., Chryssanthou, E., Borman, A., Brown, C., Guy, R., Johnson, E., Reilly, J.
External quality assessment scheme for Bordetella pertussis serology 2016
This external quality assessment (EQA) to assess the ability of national reference laboratories from EU/EEA Member States to correctly perform laboratory serodiagnostic tests for pertussis was a collaborative study organised from February to April 2016.
EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
European laboratories move forward towards stronger epidemic readiness for infectious disease threats.
The latest EULabCap data on assessing the public health laboratory capacities among 30 EU and EEA countries in 2016 reveal continuous improvement in reducing inequalities, with ten more countries reaching fair to high capability levels over the 4 years of monitoring.
Gap analysis on securing diphtheria diagnostic capacity and diphtheria antitoxin availability in the EU/EEA
This gap analysis demonstrated that there are significant gaps in diphtheria diagnostic capacity within the EU/EEA, with only six Member States fulfilling the minimum criteria in terms of surveillance, specialised laboratory diagnostics and expertise.
EU Laboratory Capability Monitoring System (EULabCap): Report on 2015 survey of EU/EEA country capabilities and capacities
This report for 2015, which presents the indicator results for EU and EEA (European Economic Area) countries, aims to help policymakers identify possible areas for action and to evaluate the impact of capacity strengthening activities and health system reforms.
EU Laboratory Capability Monitoring System (EULabCap): Report on 2014 survey of EU/EEA country capabilities and capacities
This second EULabCap report, on 2014 data presents the indicator results for EU and EEA (European Economic Area) countries, aims to help policymakers identify possible areas for action and to evaluate the impact of capacity strengthening activities and health system reforms.